Compound atlas
Growth
CJC-1295
Also known as · Modified GRF 1-29 · DAC
Half-life
168h
approx. mean t½
Dose range
1–2 mg / week
typical, not prescriptive
Category
Growth
primary use-case
— Overview
A long-acting GHRH analog (with DAC) that stimulates pulsatile growth hormone release. Often stacked with Ipamorelin.
— Mechanism of action
Binds GHRH receptors on pituitary somatotrophs, triggering endogenous GH release. DAC version extends half-life via albumin binding.
— Typical protocol
1–2 mg subQ weekly. Often combined with Ipamorelin 200–300 mcg 1–3× daily.
— Storage
Reconstituted: refrigerated, ~30 days. Lyophilized: long-term stable.
Disclaimer
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.